Antibody Analytics is pleased to welcome Paul McCluskey as our new Chair of the Board. This appointment follows our recent minority investment from NorthEdge, marking a significant phase in Antibody Analytics’ growth. Paul joins us with a rich history in finance and management, particularly in the private equity healthcare and biotech sectors, making him an invaluable addition to our team.
Paul's track record of driving growth in companies like Concept Life Sciences and Synexus Clinical Research is closely aligned with our strategic goals at Antibody Analytics. His expertise will be vital as we continue to innovate in the fields of biologics and immunology.
Commenting on his new role, Paul McCluskey said, "Joining Antibody Analytics is an exciting step for me. This company has a dynamic approach to biotech, and I'm eager to contribute to its growth and success. I believe we have a great opportunity to make significant advancements in the industry."
Andy Upsall, founder of Antibody Analytics, also shared his thoughts: "Paul's joining marks a pivotal moment for us. His no-nonsense, goal-focused approach is just what we need at this stage. His industry insights and experience will be significant as we move ahead in our mission to excel in biologics and immunology."
Paul's financial expertise, gained through roles at GlaxoSmithKline plc and KPMG’s healthcare consulting team, and his status as a fellow of the Institute of Chartered Accountants in England and Wales, will be a key asset in his role at Antibody Analytics.Top of Form
Paul's appointment marks a significant milestone in our journey. His track record of driving growth and innovation in private equity biotech and healthcare aligns perfectly with our mission. We look forward to benefiting from his expertise and leadership to propel Antibody Analytics towards new heights in the biologics and immunology spaces. Welcome aboard, Paul!